What Europe’s spinouts need to capitalise on deeptech boom: patient capital, customer obsession and support for female founders

I spend a lot of time talking to founders who are trying to build things that actually matter. Not another meme coin factory or a wrapper for a GPT model, but real deeptech—the kind of work that involves hardware, biology, and hard science. Europe has always been a powerhouse for this kind of research. Our universities are second to none when it comes to raw intellectual output. But there is a massive gap between a brilliant PhD thesis and a company that survives five years in the market.

The current landscape for European spinouts is a mix of massive potential and institutional frustration. We have the brains, but we are still struggling with the plumbing. If we want to capitalize on the current boom, we have to stop treating these companies like software startups and start treating them like the long-term infrastructure plays they are.

The Patient Capital Problem

The biggest hurdle for any deeptech founder is time. In the software world, you can ship a beta in a weekend and iterate based on user feedback by Monday. In deeptech, you might spend four years just proving that your technology doesn't violate the laws of physics. Traditional venture capital is often too impatient for this. Most funds operate on a ten-year cycle, expecting a return by year seven or eight. For a company building a fusion reactor or a new class of semiconductors, that timeline is a death sentence.

We need more patient capital. This isn't just a buzzword; it refers to investors who understand that the payoff for deeptech is binary and massive, but it requires a decade of nurturing. Europe has plenty of early-stage grants, but the 'valley of death' between a government grant and a Series B round is where most of our best ideas go to die. Founders are forced to spend half their time fundraising instead of in the lab, which slows down the very innovation they are trying to sell.

University Friction and Equity Splits

One of the quietest killers of European innovation is the cap table. In many European jurisdictions, universities take a massive chunk of equity—sometimes up to 50%—just for letting the founder take their own research out of the lab. From a founder's perspective, this is a non-starter. If a university owns half the company before an angel investor even looks at it, there is no room left for the people doing the work or the investors providing the fuel.

We are seeing some progress here, with institutions like Imperial College and others moving toward more founder-friendly terms, but the standard needs to shift across the continent. A university should view a spinout as a success for their reputation and ecosystem, not just a short-term cash grab. If you dilute the founders too early, they lose the incentive to grind through the hard years.

Moving From Research to Customer Obsession

I see a lot of academic founders fall into the trap of falling in love with their tech rather than the problem it solves. Being the smartest person in the room doesn't matter if nobody wants to buy what you're building. Deeptech isn't exempt from the rules of business. You still need to find a customer, understand their pain points, and build a product that fits their workflow.

The most successful spinouts I've seen are the ones where the lead scientist partners with a commercial-minded co-founder early on. You need someone who is obsessed with the market while the scientists are obsessed with the specs. Europe’s ecosystem needs to facilitate these marriages more effectively. We have enough researchers; we don't have enough builders who know how to sell to enterprise giants.

The Diversity Gap in Deeptech

We also have to address the fact that we are leaving half our talent on the sidelines. Data shows that female-led spinouts in Europe receive a fraction of the funding that all-male teams do. This isn't just about social equity; it’s about math. If you are ignoring a huge demographic of researchers and engineers because of systemic bias or a lack of networking opportunities, you are missing out on alpha.

Deeptech is hard enough as it is. We can't afford to have a leaky bucket where talented women leave the ecosystem because they can't get the same institutional support as their male counterparts. Support systems, mentorship, and transparent funding processes aren't 'nice to haves'—they are requirements for a competitive economy.

What Builders Should Do

If you are a founder looking to spin out a company in this environment, my advice is to be ruthless about your equity and your market fit. Do not accept terms from a university that will make you uninvestable in three years. Negotiate hard. Most importantly, start talking to potential customers before you even leave the lab. The tech might be 'deep,' but the business model should be simple: solve a high-value problem for someone who has the budget to pay for it.

Europe has a window of opportunity right now. With the global focus on AI and energy transition, the demand for hard science has never been higher. But we won't win by just having the best papers. We win by building the best companies. That means fixing the capital stacks, cleaning up the cap tables, and making sure the people doing the work actually own the upside.

Takeaway for Founders

• Fight for your cap table: If a university asks for more than 10-15%, walk away or renegotiate. High equity stakes from non-active partners kill future funding rounds.
• Optimize for time, not just valuation: Seek out investors who have a history of sticking with deeptech through long R&D cycles.
• Bridge the commercial gap: If you are a scientist, find your business counterpart early. Customer discovery is just as important as laboratory discovery.

Read the original at Sifted →